Exhibit 10.17 APPENDIX A TO PARTICIPATION AGREEMENTParticipation Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances
BETWEENLease Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Maryland
andRights Agreement • May 28th, 1998 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Delaware
among EAGLEFUNDING CAPITAL CORPORATION as Conduit,Security Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 2.1 AGREEMENT AND PLAN OF REORGANIZATIONAgreement and Plan of Reorganization • September 21st, 2000 • Human Genome Sciences Inc • Services-commercial physical & biological research • Delaware
RECITALSLease Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Maryland
BETWEENLease Agreement • March 17th, 2000 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Maryland
2 3 Prospectus, as the case may be, and any reference to any amendment or supplement to any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any document filed under the Securities Exchange Act of 1934 (the "Exchange...Human Genome Sciences Inc • March 12th, 1997 • In vitro & in vivo diagnostic substances • New York
INDENTUREIndenture • June 28th, 1999 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
HUMAN GENOME SCIENCES, INC. ISSUER ANDHuman Genome Sciences Inc • September 6th, 2000 • Services-commercial physical & biological research • New York
EMPLOYMENT AGREEMENT THIS AGREEMENT dated the 25th day of February, 1997 (the "Effective Date") between HUMAN GENOME SCIENCES, INC., a Delaware corporation (the "Corporation") and William A. Haseltine, Ph.D. (the "Employee"). WITNESSETH: WHEREAS, the...Employment Agreement • March 31st, 1997 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Maryland
INDENTUREHuman Genome Sciences Inc • February 2nd, 2000 • In vitro & in vivo diagnostic substances • New York
HUMAN GENOME SCIENCES, INC. ISSUER ANDHuman Genome Sciences Inc • September 6th, 2000 • Services-commercial physical & biological research • New York
JOINT FILING AGREEMENTJoint Filing Agreement • September 3rd, 2004 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances
The undersigned hereby agree that the Statement on this Schedule 13G, dated August 19, 2004, (the "Schedule 13G"), with respect to the Common Stock, $0.01 par value per share, of Human Genome Sciences Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
Portions of this Exhibit have been omitted pursuant to a request for confidential treatment. The omitted portions, marked by [****], have been separately filed with the Commission." RESEARCH COLLABORATION AGREEMENT This Agreement, effective January...Collaboration Agreement • October 1st, 1996 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Maryland
1 EXHIBIT 1.1 HUMAN GENOME SCIENCES, INC. UNDERWRITING AGREEMENT BASIC TERMS 1. Introductory. Human Genome Sciences, Inc., a Delaware corporation ("COMPANY"), proposes to issue and sell from time to certain of its unsecured debt securities, preferred...Terms Agreement • September 6th, 2000 • Human Genome Sciences Inc • Services-commercial physical & biological research • New York
EXHIBIT 4.2 CONFORMED COPY Up to $225,000,000 Human Genome Sciences, Inc. 5% Convertible Subordinated Notes Due February 1, 2007 REGISTRATION RIGHTS AGREEMENTHuman Genome Sciences Inc • February 2nd, 2000 • In vitro & in vivo diagnostic substances • New York
Portions of this Exhibit have been omitted pursuant to a request for confidential treatment. The omitted portions, marked by [***], have been separately filed with the Commission." Merck/SB/HGS ------------ COLLABORATION AND LICENSE AGREEMENT...Collaboration and License Agreement • March 12th, 1997 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Pennsylvania
LICENSE AGREEMENTHuman Genome Sciences Inc • October 1st, 1996 • In vitro & in vivo diagnostic substances • Delaware
GUARANTEE byGuarantee • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Maryland
EXHIBIT 4.2 Up to $350,000,000 Human Genome Sciences, Inc. 3 3/4% Convertible Subordinated Notes Due March 15, 2007 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 13th, 2000 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
1 EXHIBIT 4.2 ----------- Up to $125,000,000 Human Genome Sciences, Inc. 5-1/2% Convertible Subordinated Notes due July 1, 2006 REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 28th, 1999 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
1 EXHIBIT 1.1 DEALER MANAGER AGREEMENTDealer Manager Agreement • December 7th, 1999 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
ARTICLE II. LEASE OF PROPERTYLease Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances
EXHIBIT 10.23 CASH COLLATERAL PLEDGE AGREEMENTCollateral Pledge Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Maryland
Exhibit 10.19 CONSTRUCTION AGENCY AGREEMENTConstruction Agency Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
1.1 "AFFILIATES" shall mean any individual or entity directly or indirectly controlling, controlled by or under common control with, the specified individual or entity. For purposes of this Agreement, the direct or indirect ownership of over fifty...Human Genome Sciences Inc • March 12th, 1997 • In vitro & in vivo diagnostic substances • Delaware
REGISTRATION RIGHTS AGREEMENT by and among HUMAN GENOME SCIENCES, INC. and THE INITIAL PURCHASERS NAMED HEREIN Dated August 9, 2005Registration Rights Agreement • August 9th, 2005 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
Registration Rights Agreement (this “Agreement”), dated as of August 9, 2005, by and among Human Genome Sciences, Inc., a Delaware corporation (together with any successor entity, the “Issuer”) and Citigroup Global Markets Inc. (“Citigroup”) and Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) (each, an “Initial Purchaser” and, collectively, the “Initial Purchasers”).
Human Genome Sciences, Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • December 8th, 2009 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
Human Genome Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 15,500,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,325,000 additional shares (the “Optional Shares”) of common stock, par value $0.01 per share (“Common Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
1 EXHIBIT 10.66 GENE THERAPY COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • July 10th, 1998 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Delaware
FORM OF INDEMNIFICATION AGREEMENTForm of Indemnification Agreement • July 22nd, 2010 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Delaware
This Indemnification Agreement, dated as of , 2010, is made by and between Human Genome Sciences, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”).
INDENTUREHuman Genome Sciences Inc • December 16th, 1999 • In vitro & in vivo diagnostic substances • New York
RIGHTS AGREEMENT dated as of May 16, 2012 between HUMAN GENOME SCIENCES, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC as Rights AgentRights Agreement • May 17th, 2012 • Human Genome Sciences Inc • Biological products, (no disgnostic substances) • Delaware
RIGHTS AGREEMENT (as amended from time to time, this “Agreement”), dated as of May 16, 2012 between Human Genome Sciences, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as Rights Agent (the “Rights Agent,” which term shall include any successor Rights Agent hereunder).
AMENDMENT NO. 1 TO RIGHTS AGREEMENTRights Agreement • July 17th, 2012 • Human Genome Sciences Inc • Biological products, (no disgnostic substances) • Delaware
This AMENDMENT NO. 1 (this “Amendment”) to the Rights Agreement dated as of May 16, 2012 (the “Rights Agreement”) between Human Genome Sciences, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, as rights agent (the “Rights Agent”), is entered into as of July 16, 2012. Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings given to them in the Rights Agreement.
AMENDED AND RESTATED AGENCY AGREEMENT Dated as of June 30, 2003 between HUMAN GENOME SCIENCES, INC., as the Construction Agent, and WACHOVIA DEVELOPMENT CORPORATION, as the LessorAgency Agreement • August 11th, 2003 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • New York
THIS AMENDED AND RESTATED AGENCY AGREEMENT, dated as of June 30, 2003 (as amended, modified, extended, supplemented and/or restated from time to time, the “Agreement”), is between WACHOVIA DEVELOPMENT CORPORATION, a North Carolina corporation (the “Lessor”) and HUMAN GENOME SCIENCES, INC., a Delaware corporation (the “Construction Agent”).
